LumiraDx
LumiraDx, CA Healthcare Acquisition Revise Merger Terms to Lower Equity Value of Combined Company
The firms said that lowering the pro forma enterprise value of post-merger LumiraDx is expected to make the new company more attractive to investors.
Thermo Fisher Scientific, Access Bio, LumiraDx Get FDA EUAs for SARS-CoV-2 Tests
Thermo Fisher's test is designed to detect SARS-CoV-2 nucleic acid, while Access Bio's test detects viral antigens and LumiraDx's detects antibodies against the virus.
LumiraDx Gets CE Mark for Molecular SARS-CoV-2 Test
The PCR-based test first received Emergency Use Authorization from the US Food and Drug Administration in late 2020.
LumiraDx to Go Public on Nasdaq Through SPAC
CA Healthcare Acquisition, a special purpose acquisition company, said the transaction will support the development of LumiraDx’s pipeline of more than 30 assays.
LumiraDx Gets FDA Emergency Use Authorization for PCR-Based Coronavirus Test
The assay does not require nucleic acid extraction or purification, unlike a LumiraDx SARS-CoV-2 test that received Emergency Use Authorization in August.